BR112012007411A2 - composto, processo para sua preparação e composição farmacêutica contendo o mesmo - Google Patents

composto, processo para sua preparação e composição farmacêutica contendo o mesmo

Info

Publication number
BR112012007411A2
BR112012007411A2 BR112012007411A BR112012007411A BR112012007411A2 BR 112012007411 A2 BR112012007411 A2 BR 112012007411A2 BR 112012007411 A BR112012007411 A BR 112012007411A BR 112012007411 A BR112012007411 A BR 112012007411A BR 112012007411 A2 BR112012007411 A2 BR 112012007411A2
Authority
BR
Brazil
Prior art keywords
group
optionally substituted
preparation
pharmaceutical composition
compound
Prior art date
Application number
BR112012007411A
Other languages
English (en)
Other versions
BR112012007411B8 (pt
BR112012007411B1 (pt
Inventor
Alzpea Zubia Olascoaga
Dorleta Otaegui Ansa
Eider San Sebastián Larzabal
Eneko Aldaba Arévalo
Fernando Pedroso Cossío Mora
María Del Carmen Masdeu Margalef
Yosu Ion Vara Salazar
Original Assignee
Ikerchem S L
Univ Del País Vasco
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ikerchem S L, Univ Del País Vasco filed Critical Ikerchem S L
Publication of BR112012007411A2 publication Critical patent/BR112012007411A2/pt
Publication of BR112012007411B1 publication Critical patent/BR112012007411B1/pt
Publication of BR112012007411B8 publication Critical patent/BR112012007411B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

composto, processo para sua preparação e composição farmacêutica contendo o mesmo. a presente invenção refere-se a compostos derivados de anéis de 1h-pirrol trissubstituído e anéis aromáticos, que têm a seguinte fórmula (i): em que ; r^ 1^ e r^ 2^ representam, independentemente, um radical arila c~ 6~-c~ 10~ opcionalmente substituído ou um radical heteroarila opcionalmente substituído; a e m representam, independentemente, um grupo matileno ou uma ligação simples, neste caso, o anel aromático adjacente estaria anexado diretamente ao grupo amida; o grupo y=z representa juntamente e indistintamente um átomo de oxigênio, um átomo de enxofre, um grupo cis-vinilideno, um grupo imino, ou um grupo metino com um átomo de carbono hibridizado sp^ 2^; x representa indistintamente em grupo metino, um grupo cis-vinilideno ou um átomo de nitrogênio; e w representa um grupo hidroxila, um grupo alquila c~ 1~-c~ 6~ opcionalmente substituído, um grupo heteroarila opcionalmente substituído ou um grupo arila c~ 6~-c~ 10~ opcionalmente substituído; ou um sal, solvato ou pró-droga do mesmo, bem como o processo para sua preparação e o uso do mesmo para tratamento de câncer.
BR112012007411A 2009-10-02 2010-10-01 composto, processo para sua preparação e composição farmacêutica contendo o mesmo BR112012007411B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09382193A EP2305643A1 (en) 2009-10-02 2009-10-02 New histone deacetylase inhibitors based simultaneously on trisubstituted 1h-pyrroles and aromatic and heteroaromatic spacers
EP09382193.2 2009-10-02
PCT/EP2010/064653 WO2011039353A1 (en) 2009-10-02 2010-10-01 New histone deacetylase inhibitors based simultaneously on trisubstituted 1h-pyrroles and aromatic and heteroaromatic spacers

Publications (3)

Publication Number Publication Date
BR112012007411A2 true BR112012007411A2 (pt) 2016-12-06
BR112012007411B1 BR112012007411B1 (pt) 2020-12-15
BR112012007411B8 BR112012007411B8 (pt) 2021-05-25

Family

ID=41716282

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012007411A BR112012007411B8 (pt) 2009-10-02 2010-10-01 composto, processo para sua preparação e composição farmacêutica contendo o mesmo

Country Status (17)

Country Link
US (1) US8685992B2 (pt)
EP (2) EP2305643A1 (pt)
JP (1) JP5746185B2 (pt)
KR (1) KR101754940B1 (pt)
CN (1) CN102648177B (pt)
AU (1) AU2010302572B2 (pt)
BR (1) BR112012007411B8 (pt)
CA (1) CA2776351C (pt)
ES (1) ES2452868T3 (pt)
HK (1) HK1173450A1 (pt)
IL (1) IL218995A (pt)
IN (1) IN2012DN03129A (pt)
MX (1) MX2012003988A (pt)
PL (1) PL2483242T3 (pt)
PT (1) PT2483242E (pt)
RU (1) RU2549885C2 (pt)
WO (1) WO2011039353A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011313853A1 (en) * 2010-10-11 2013-05-02 Auckland Uniservices Limited Substituted benzamides and their uses
RU2634694C2 (ru) * 2013-04-29 2017-11-03 Чонг Кун Данг Фармасьютикал Корп. Новые соединения для селективных ингибиторов гистондеацетилазы и фармацевтическая композиция, включающая такие соединения
TW201636329A (zh) 2015-02-02 2016-10-16 佛瑪治療公司 作為ｈｄａｃ抑制劑之雙環［４，６，０］異羥肟酸
US10112915B2 (en) 2015-02-02 2018-10-30 Forma Therapeutics, Inc. 3-aryl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
US20180251425A1 (en) * 2015-08-17 2018-09-06 University Of Mysore 2,3,5 trisubstituted pyrrole derivatives as topoisomerase inhibitors and therapeutic uses thereof
US10555935B2 (en) 2016-06-17 2020-02-11 Forma Therapeutics, Inc. 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors
CN107793375A (zh) * 2016-08-31 2018-03-13 中国科学院上海药物研究所 一类芳基2,2’‑串联双噻唑类化合物及其制备方法和用途
EP3318256A1 (en) * 2016-11-08 2018-05-09 Quimatryx, S.L Compounds for the treatment of autoimmune diseases
GB201708457D0 (en) 2017-05-26 2017-07-12 Univ Oxford Innovation Ltd Inhibitors of metallo-beta-lactamases
CN110938055A (zh) * 2018-09-21 2020-03-31 华东师范大学 六元环甲酰胺类化合物及其合成方法和应用
EP3956324B1 (en) 2019-04-17 2024-02-21 Quimatryx, S.L. 1,3,4-oxadiazole derivatives as histone deacetylase inhibitors
CN112225737B (zh) * 2020-12-11 2021-04-09 北京鑫开元医药科技有限公司 具有hdac抑制活性的化合物、制备方法、组合物及用途
CN112516142B (zh) * 2020-12-11 2021-10-15 北京华氏精恒医药科技有限公司 一种具有hdac抑制活性的药物组合物、制备方法及其用途
CN116813560A (zh) * 2022-03-28 2023-09-29 上海科技大学 三唑酰胺类化合物及其制备方法和用途
CN114558004B (zh) * 2022-03-29 2023-08-11 奎马特里克斯有限公司 Qtx125药物制剂
CN114634489B (zh) * 2022-04-19 2023-07-04 奎马特里克斯有限公司 结晶形式
CN114652715B (zh) 2022-04-29 2023-04-25 奎马特里克斯有限公司 联合疗法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA76977C2 (en) * 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
US7781595B2 (en) 2003-09-22 2010-08-24 S*Bio Pte Ltd. Benzimidazole derivatives: preparation and pharmaceutical applications
BRPI0417138A (pt) * 2003-12-05 2007-02-21 Warner Lambert Co n-alquil-pirroles como inibidores de hmg-coa-redutase
US20090298905A1 (en) * 2005-04-15 2009-12-03 Fernando Pedro Cossio Nitrogenatd trans-stilbene analogs, method for the obtention and medical applications thereof
US7754717B2 (en) * 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
WO2007074176A1 (es) * 2005-12-27 2007-07-05 Universidad Del Pais Vasco - Euskal Herriko Unibertsitatea (Upv-Ehu) Nuevos derivados pirrólicos con actividad inhibidora de desacetilasas de histonas
CA2703718A1 (en) * 2007-11-02 2009-05-07 Tammy Mallais Inhibitors of histone deacetylase

Also Published As

Publication number Publication date
RU2549885C2 (ru) 2015-05-10
EP2483242A1 (en) 2012-08-08
HK1173450A1 (en) 2013-05-16
JP2013506637A (ja) 2013-02-28
PT2483242E (pt) 2014-03-17
AU2010302572B2 (en) 2016-10-20
IN2012DN03129A (pt) 2015-09-18
EP2483242B1 (en) 2013-12-11
AU2010302572A8 (en) 2012-05-24
MX2012003988A (es) 2012-07-23
KR101754940B1 (ko) 2017-07-06
IL218995A0 (en) 2012-06-28
CA2776351C (en) 2017-10-31
EP2305643A1 (en) 2011-04-06
ES2452868T3 (es) 2014-04-03
CA2776351A1 (en) 2011-04-07
JP5746185B2 (ja) 2015-07-08
WO2011039353A1 (en) 2011-04-07
US8685992B2 (en) 2014-04-01
BR112012007411B8 (pt) 2021-05-25
KR20120091176A (ko) 2012-08-17
CN102648177B (zh) 2015-01-07
AU2010302572A1 (en) 2012-05-17
PL2483242T3 (pl) 2014-05-30
US20120196885A1 (en) 2012-08-02
BR112012007411B1 (pt) 2020-12-15
RU2012117885A (ru) 2013-11-10
IL218995A (en) 2016-11-30
CN102648177A (zh) 2012-08-22

Similar Documents

Publication Publication Date Title
BR112012007411A2 (pt) composto, processo para sua preparação e composição farmacêutica contendo o mesmo
IN2014DN03325A (pt)
BR112012019762A2 (pt) composto, composição, e, método para tratar uma doença.
UY32074A (es) Compuestos de pirrol
MX2010007587A (es) Compuestos que comprenden un grupo ciclobutoxi.
BR112012006031A2 (pt) processo para preparação de compostos azabicíclicos.
BR112012033350A2 (pt) "composição e métodos para modular a via de sinalização de wnt"
BR112012030923B8 (pt) Composto derivado de piperidinona como inibidor de mdm2 e composição farmacêutica compreendendo o mesmo
BR112012026950A2 (pt) composto, e, uso de um composto
MY159850A (en) Tetracyclic compounds
BRPI0813284A8 (pt) Processo para a preparação de um composto da fórmula (i) e composto
BRPI0514644A (pt) composto fosforamidita, composto ácido ribonucléico, e método para produzir oligo-rna
EA201200102A1 (ru) Соединения, применимые в качестве лекарственных средств
ATE477234T1 (de) Synthese von phenolischen estern von hydroxymethylphenolen
EP2575815A4 (en) GLYCIN TRANSPORTER 1 INHIBITORS, METHODS OF MAKING THE SAME, AND USES THEREOF
MX2014005870A (es) Proceso para preparar compuestos de 1h -pirazol - 5 - carboxilato n - sustituidos y derivados de los mismos.
BR112013024223A2 (pt) composto de poliéter, agente de cura usando o composto de poliéter, e método de produção do composto de poliéter
BR112013011172A2 (pt) compostos antidiabéticos
BR112014010644A2 (pt) novos derivados de aril-quinolina
BRPI1014802B8 (pt) profármacos de triptolida.
BR112012006176A2 (pt) inibidores macrocíclicos de jak
EA200900090A1 (ru) Бензиламины, способ их получения и их применение в качестве противовоспалительных средств
DE602006019870D1 (de) Verfahren zur synthese von triazolen
BR112012031340A2 (pt) derivados de cianoquinolina
BR122018074306B8 (pt) Método para preparar um composto de fórmula 1a

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 15/12/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/10/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF